Oliver Schmetzer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Oliver Schmetzer has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
Martin K. Church
Dept. of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Germany
6 shared publicationsMarcus Maurer
Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany
4 shared publications- Marcus Maurer
Institute of Allergology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
4 shared publications - José Ricardo Pires
Universidade Federal do Rio de Janeiro
3 shared publications - Martin Metz
Institute of Allergology Charité – Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt‐Universität zu Berlin Berlin Germany
3 shared publications - Ana Paula Cabral Araujo Lima
Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
2 shared publications
Latest Publications
- Open Access
- 8 January 2026
- Published by Walter de Gruyter GmbH in Journal of Laboratory Medicine
- Vol. 50 (2) , 66-72
The real-world rate of falsely reduced cardiac troponin T tests
Objectives: Measurement of cardiac troponin T (cTnT) plays a crucial role in the diagnosis of acute myocardial infarction (AMI). Due to its extremely high sensitivity, the high sensitive troponin T test is vulnerable to interfering antibodies. Development of antibodies against troponin T is an example of “autoimmunization” due to an altered self. Incorrect, reduced troponin T test results are commonly observed with a deviation of more than 40 % compared to the real value. According to literature 10–20 % of measurements reveal such inaccurate results. This rate is even higher in the most relevant risk group, patients who already had suffered from an AMI. Methods: For this purpose, we spiked serum samples with a defined amount of recombinant troponin T and analyzed the recovery rate. Here, a differing result indicates presence of troponin T analyte interference. 147 consecutive selected samples with cTnT results up to 200 pg/mL were reanalyzed for a negative interference of the test by adding recombinant troponin T protein as a spike to each serum sample and thereafter retesting the sample again. Results: 35 % of the samples (n=51) had an interference of at least 40 %, an interference of at least 80 % was found in 10 % (n=12). Conclusions: This means, that in 10 % of the patients a clinically relevant masked laboratory test result was observed, revealing at least fivefold higher troponin concentrations than reported by routine analysis.
- 8 January 2026
- Published by Walter de Gruyter GmbH in Journal of Laboratory Medicine
- Vol. 50 (2) , 66-72
Open AccessThe real-world rate of falsely reduced cardiac troponin T tests
Objectives: Measurement of cardiac troponin T (cTnT) plays a crucial role in the diagnosis of acute myocardial infarction (AMI). Due to its extremely high sensitivity, the high sensitive troponin T test is vulnerable to interfering antibodies. Development of antibodies against troponin T is an example of “autoimmunization” due to an altered self. Incorrect, reduced troponin T test results are commonly observed with a deviation of more than 40 % compared to the real value. According to literature 10–20 % of measurements reveal such inaccurate results. This rate is even higher in the most relevant risk group, patients who already had suffered from an AMI. Methods: For this purpose, we spiked serum samples with a defined amount of recombinant troponin T and analyzed the recovery rate. Here, a differing result indicates presence of troponin T analyte interference. 147 consecutive selected samples with cTnT results up to 200 pg/mL were reanalyzed for a negative interference of the test by adding recombinant troponin T protein as a spike to each serum sample and thereafter retesting the sample again. Results: 35 % of the samples (n=51) had an interference of at least 40 %, an interference of at least 80 % was found in 10 % (n=12). Conclusions: This means, that in 10 % of the patients a clinically relevant masked laboratory test result was observed, revealing at least fivefold higher troponin concentrations than reported by routine analysis.
- Open Access
- 12 March 2021
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 12
Anti-aquaporin 4 IgG Is Not Associated With Any Clinical Disease Characteristics in Neuromyelitis Optica Spectrum Disorder
Background:Neuromyelitis optica spectrum disorder (NMOSD) is a clinically defined, inflammatory central nervous system (CNS) disease of unknown cause, associated with humoral autoimmune findings such as anti-aquaporin 4 (AQP4)-IgG. Recent clinical trials showed a benefit of anti-B cell and anti-complement-antibodies in NMOSD, suggesting relevance of anti-AQP4-IgG in disease pathogenesis.Objective:AQP4-IgG in NMOSD is clearly defined, yet up to 40% of the patients are negative for AQP4-IgG. This may indicate that AQP4-IgG is not disease-driving in NMOSD or defines a distinct patient endotype.Methods:We established a biobank of 63 clinically well-characterized NMOSD patients with an extensive annotation of 351 symptoms, patient characteristics, laboratory results and clinical scores. We used phylogenetic clustering, heatmaps, principal component and longitudinal causal interference analyses to test for the relevance of anti-AQP4-IgG.Results:Anti-AQP4-IgG was undetectable in 29 (46%) of the 63 NMOSD patients. Within anti-AQP4-IgG-positive patients, anti-AQP4-IgG titers did not correlate with clinical disease activity. Comparing anti-AQP4-IgG-positive vs. -negative patients did not delineate any clinically defined subgroup. However, anti-AQP4-IgG positive patients had a significantly (p= 0.022) higher rate of additional autoimmune diagnoses.Conclusion:Our results challenge the assumption that anti-AQP4-IgG alone plays a disease-driving role in NMOSD. Anti-AQP4-IgG might represent an epiphenomenon associated with NMOSD, may represent one of several immune mechanisms that collectively contribute to the pathogenesis of this disease or indeed, anti-AQP4-IgG might be the relevant factor in only a subgroup of patients.
- 12 March 2021
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 12
Open AccessAnti-aquaporin 4 IgG Is Not Associated With Any Clinical Disease Characteristics in Neuromyelitis Optica Spectrum Disorder
Background:Neuromyelitis optica spectrum disorder (NMOSD) is a clinically defined, inflammatory central nervous system (CNS) disease of unknown cause, associated with humoral autoimmune findings such as anti-aquaporin 4 (AQP4)-IgG. Recent clinical trials showed a benefit of anti-B cell and anti-complement-antibodies in NMOSD, suggesting relevance of anti-AQP4-IgG in disease pathogenesis.Objective:AQP4-IgG in NMOSD is clearly defined, yet up to 40% of the patients are negative for AQP4-IgG. This may indicate that AQP4-IgG is not disease-driving in NMOSD or defines a distinct patient endotype.Methods:We established a biobank of 63 clinically well-characterized NMOSD patients with an extensive annotation of 351 symptoms, patient characteristics, laboratory results and clinical scores. We used phylogenetic clustering, heatmaps, principal component and longitudinal causal interference analyses to test for the relevance of anti-AQP4-IgG.Results:Anti-AQP4-IgG was undetectable in 29 (46%) of the 63 NMOSD patients. Within anti-AQP4-IgG-positive patients, anti-AQP4-IgG titers did not correlate with clinical disease activity. Comparing anti-AQP4-IgG-positive vs. -negative patients did not delineate any clinically defined subgroup. However, anti-AQP4-IgG positive patients had a significantly (p= 0.022) higher rate of additional autoimmune diagnoses.Conclusion:Our results challenge the assumption that anti-AQP4-IgG alone plays a disease-driving role in NMOSD. Anti-AQP4-IgG might represent an epiphenomenon associated with NMOSD, may represent one of several immune mechanisms that collectively contribute to the pathogenesis of this disease or indeed, anti-AQP4-IgG might be the relevant factor in only a subgroup of patients.
- 26 April 2019
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 33 (9) , 1747-1754
Immunological effects and potential mechanisms of action of autologous serum therapy in chronic spontaneous urticaria
Background: Autoimmune processes are considered to play a major role in the pathogenesis of chronic spontaneous urticaria (CSU). Very recently, interleukin 24 (IL‐24) has been identified as an immunoglobulin E (IgE) autoantigen in CSU. Some studies revealed that notably autologous serum skin test (ASST)‐positive CSU patients may benefit from autohemotherapy; however, the mechanisms of action remain unknown. We aimed to investigate the immunological effects of autologous serum injections in ASST‐positive CSU patients.Methods: Sixty‐six ASST‐positive CSU patients were treated with weekly intramuscular autologous serum injections for 8 weeks and followed up for 12 weeks. Urticaria activity score (UAS7) and Dermatology Life Quality Index (DLQI) were assessed. The ASST was done at baseline, week 9 and week 21. Serum samples (baseline, weeks 9, 13 and/or 21) were analysed for the levels of IgE‐anti‐IL‐24 and immunoglobulin G (IgG)‐anti‐IL‐24 via ELISA and their ability to release histamine in basophils [basophil histamine release assay (BHRA)].Results: Autologous serum therapy resulted in a substantial improvement in disease activity and quality of life after 8 and 20 weeks. Twenty‐eight percent and 34% of patients turned ASST‐negative in weeks 9 and 21, respectively, but there was no link between their response to treatment and changes of ASST results. Also, no significant or relevant changes in BHRA were observed. In contrast, autologous serum therapy significantly decreased IgE‐anti‐IL‐24 serum levels, but not IgG‐anti‐IL‐24 serum levels, in responders but not in non‐responders.Conclusions: Our findings suggest that the immunological effects of autologous serum therapy include a reduction in IgE‐anti‐IL24 autoantibodies, which may contribute to the pathogenesis of CSU.
- 26 April 2019
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 33 (9) , 1747-1754
Immunological effects and potential mechanisms of action of autologous serum therapy in chronic spontaneous urticaria
Background: Autoimmune processes are considered to play a major role in the pathogenesis of chronic spontaneous urticaria (CSU). Very recently, interleukin 24 (IL‐24) has been identified as an immunoglobulin E (IgE) autoantigen in CSU. Some studies revealed that notably autologous serum skin test (ASST)‐positive CSU patients may benefit from autohemotherapy; however, the mechanisms of action remain unknown. We aimed to investigate the immunological effects of autologous serum injections in ASST‐positive CSU patients.Methods: Sixty‐six ASST‐positive CSU patients were treated with weekly intramuscular autologous serum injections for 8 weeks and followed up for 12 weeks. Urticaria activity score (UAS7) and Dermatology Life Quality Index (DLQI) were assessed. The ASST was done at baseline, week 9 and week 21. Serum samples (baseline, weeks 9, 13 and/or 21) were analysed for the levels of IgE‐anti‐IL‐24 and immunoglobulin G (IgG)‐anti‐IL‐24 via ELISA and their ability to release histamine in basophils [basophil histamine release assay (BHRA)].Results: Autologous serum therapy resulted in a substantial improvement in disease activity and quality of life after 8 and 20 weeks. Twenty‐eight percent and 34% of patients turned ASST‐negative in weeks 9 and 21, respectively, but there was no link between their response to treatment and changes of ASST results. Also, no significant or relevant changes in BHRA were observed. In contrast, autologous serum therapy significantly decreased IgE‐anti‐IL‐24 serum levels, but not IgG‐anti‐IL‐24 serum levels, in responders but not in non‐responders.Conclusions: Our findings suggest that the immunological effects of autologous serum therapy include a reduction in IgE‐anti‐IL24 autoantibodies, which may contribute to the pathogenesis of CSU.
- Open Access
- 1 January 2019
- Published by Ivyspring International Publisher in Theranostics
- Vol. 9 (3) , 829-836
On the Lipophilic Nature of Autoreactive IgE in Chronic Spontaneous Urticaria
Chronic spontaneous urticaria (CSU) is a skin disease related to autoreactive IgE in at least a subgroup of patients. However, the nature of this autoreactive IgE remains poorly characterized. This investigation had three objectives: first, to quantity CSU autoreactive IgE; second, to recognize the patterns of CSU autoreactive IgE compared with healthy control IgE; and third, to investigate the physiochemical nature of CSU autoreactive IgE.
- 1 January 2019
- Published by Ivyspring International Publisher in Theranostics
- Vol. 9 (3) , 829-836
Open AccessOn the Lipophilic Nature of Autoreactive IgE in Chronic Spontaneous Urticaria
Chronic spontaneous urticaria (CSU) is a skin disease related to autoreactive IgE in at least a subgroup of patients. However, the nature of this autoreactive IgE remains poorly characterized. This investigation had three objectives: first, to quantity CSU autoreactive IgE; second, to recognize the patterns of CSU autoreactive IgE compared with healthy control IgE; and third, to investigate the physiochemical nature of CSU autoreactive IgE.
- Top Cited Papers
- 1 September 2018
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 142 (3) , 876-882
IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria
- 1 September 2018
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 142 (3) , 876-882
Top Cited PapersIL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria
- Open Access
- 9 April 2018
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 9, 689
Immunoglobulin E-Mediated Autoimmunity
The study of autoimmunity mediated by immunoglobulin E (IgE) autoantibodies, which may be termed autoallergy, is in its infancy. It is now recognized that systemic lupus erythematosus, bullous pemphigoid (BP), and chronic urticaria, both spontaneous and inducible, are most likely to be mediated, at least in part, by IgE autoantibodies. The situation in other conditions, such as autoimmune uveitis, rheumatoid arthritis, hyperthyroid Graves’ disease, autoimmune pancreatitis, and even asthma, is far less clear but evidence for autoallergy is accumulating. To be certain of an autoallergic mechanism, it is necessary to identify both IgE autoantibodies and their targets as has been done with the transmembrane protein BP180 and the intracellular protein BP230 in BP and IL-24 in chronic spontaneous urticaria. Also, IgE-targeted therapies, such as anti-IgE, must have been shown to be of benefit to patients as has been done with both of these conditions. This comprehensive review of the literature on IgE-mediated autoallergy focuses on three related questions. What do we know about the prevalence of IgE autoantibodies and their targets in different diseases? What do we know about the relevance of IgE autoantibodies in different diseases? What do we know about the cellular and molecular effects of IgE autoantibodies? In addition to providing answers to these questions, based on a broad review of the literature, we outline the current gaps of knowledge in our understanding of IgE autoantibodies and describe approaches to address them.
- 9 April 2018
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 9, 689
Open AccessImmunoglobulin E-Mediated Autoimmunity
The study of autoimmunity mediated by immunoglobulin E (IgE) autoantibodies, which may be termed autoallergy, is in its infancy. It is now recognized that systemic lupus erythematosus, bullous pemphigoid (BP), and chronic urticaria, both spontaneous and inducible, are most likely to be mediated, at least in part, by IgE autoantibodies. The situation in other conditions, such as autoimmune uveitis, rheumatoid arthritis, hyperthyroid Graves’ disease, autoimmune pancreatitis, and even asthma, is far less clear but evidence for autoallergy is accumulating. To be certain of an autoallergic mechanism, it is necessary to identify both IgE autoantibodies and their targets as has been done with the transmembrane protein BP180 and the intracellular protein BP230 in BP and IL-24 in chronic spontaneous urticaria. Also, IgE-targeted therapies, such as anti-IgE, must have been shown to be of benefit to patients as has been done with both of these conditions. This comprehensive review of the literature on IgE-mediated autoallergy focuses on three related questions. What do we know about the prevalence of IgE autoantibodies and their targets in different diseases? What do we know about the relevance of IgE autoantibodies in different diseases? What do we know about the cellular and molecular effects of IgE autoantibodies? In addition to providing answers to these questions, based on a broad review of the literature, we outline the current gaps of knowledge in our understanding of IgE autoantibodies and describe approaches to address them.
- 1 March 2018
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 141 (3) , 1166-1167
Reply
- 1 March 2018
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 141 (3) , 1166-1167
Reply
- Top Cited Papers
- 1 June 2017
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 139 (6) , 1772-1781.e1
Autoimmune chronic spontaneous urticaria: What we know and what we do not know
- 1 June 2017
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 139 (6) , 1772-1781.e1
Top Cited PapersAutoimmune chronic spontaneous urticaria: What we know and what we do not know
- 1 May 2016
- Published by Elsevier in European Journal of Pharmacology
- Vol. 778, 2-10
Murine and human mast cell progenitors
- 1 May 2016
- Published by Elsevier in European Journal of Pharmacology
- Vol. 778, 2-10
Murine and human mast cell progenitors
- 1 November 2014
- Published by Elsevier in Journal of Immunological Methods
- Vol. 413, 62-68
A novel method to generate and culture human mast cells: Peripheral CD34+ stem cell-derived mast cells (PSCMCs)
- 1 November 2014
- Published by Elsevier in Journal of Immunological Methods
- Vol. 413, 62-68
A novel method to generate and culture human mast cells: Peripheral CD34+ stem cell-derived mast cells (PSCMCs)